We care about creating quality biologics with passion

Innovative development and manufacturing solutions to get safe and effective biotherapeutics to patients.

More about us More about us

Biosimilar Ranibizumab has been accepted for review by the FDA

Bioeq's BLA for its proposed biosimilar to Lucentis® has been accepted for review.

Read

Polpharma Biologics announces 70 new vacancies

Rapid growth of Polish biotechnology sector leads to demand for foreign expertise

Read

Polpharma Biologics Group announces that its joint venture Bioeq has...

Polpharma Biologics Group announces that its joint venture company with Santo Holdin...

Read

Polpharma Biologics Group announces that its joint venture company,...

The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) that h...

Read

Press Releases Published: 04.10.2021

Polpharma Biologics Group announces that the Biologics License Application (BLA) submit...

Bioeq has received notification by the U.S. Food and Drug Administration (FDA) that the biologics license application...

Press Releases Published: 31.08.2021

Rapid growth of Polish biotechnology sector leads to demand for foreign expertise, as P...

The new roles come on top of significant growth at the company in the last two years, with an additional 300 employee...

Press Releases Published: 06.08.2021

Polpharma Biologics Group announces that its joint venture Bioeq has submitted a biolog...

Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has...

Press Releases Published: 07.07.2021

Polpharma Biologics Group announces that its joint venture company, Bioeq, has entered...

The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) that has been approved to treat the "we...

Learn more

Development & manufacturing solutions

Our innovative solutions and dedicated scientists come together to provide industry leading capabilities to take your project from idea to global supply. We don’t just provide the capabilities we also provide extensive regulatory, IP and clinical support. We are committed to positive outcomes and delivering projects on time to specification.

Learn more

Mammalian solutions

Microbial solutions

Drug product & fill finish solutions

Biosimilar solutions

Project solutions

Learn more

Mammalian solutions

All the component to take your product from DNA, through IND and clinical trials and to support your global commercial supply. This includes antibody discovery, cell line development, process development and cGMP manufacturing supported by extensive analytical capabilities.

Learn more

Microbial solutions

State of the art microbial manufacturing facilities for fermentation recovery & purification development through to cGMP manufacturing for preclinical, clinical and commercial supply.

Learn more

Drug product & fill finish solutions

Drug product development and cGMP manufacturing of sterile biologicals in liquid and lyophilized forms at lab and large-scale.

Learn more

Biosimilar solutions

Comprehensive biosimilar development capabilities from cell line development to commercial supply to help our partners provide patients access to the most advanced therapies available.

Learn more

Project solutions

We utilize our extensive experience in taking products through clinical trials to provide our partners with IP, clinical and regulatory support.

Learn more

Biosimilar portfolio

Our proprietary cell line development platform and highly efficient R&D workflows have set the stage for the development of a range of biosimilar candidates, with several in clinical trials up to stage III.

Learn more

Novel biologics portfolio

Our novel biologics pipeline utilizes the extensive discovery experience of our Utrecht site to develop innovative therapies in areas where patients need them most, including orphan diseases.

Learn more

Creating quality biologics with passion

We are passionate about providing safe and effective medicines to patients.

Delivering on our commitments

We are self-motivated to reach the end result - “wait and see” is not in our vocabulary.

Being respectful and transparent

We are open and honest without exception.

Join our team

All our staff are motivated by the same passion, getting safe and effective medicines to patients. Join us today.

Specjalista Analityki Rozwoju Produktu

Department Research and Development/ Badania i Rozwój

Location Gdańsk

Publication date 15/10/2021

Apply now

Specjalista Kontroli Jakości Materiałów

Department Quality/ Jakość

Location Duchnice (pow. warszawski zachodni)

Publication date 15/10/2021

Apply now

Drug Product Specialist

Department Technical Operations/ Operacje Techniczne

Location Gdańsk

Publication date 14/10/2021

Apply now

More available positions More available positions

Our sites

With state-of-the-art facilities across Europe, Polpharma Biologics is at the forefront of the next wave in biotechnology, leveraging our knowledge, capabilities and footprint to develop innovative solutions for the industry.

Gdańsk

Our Gdansk site includes mammalian and microbial R&D and manufacturing facilities for mid-scale production including drug product and fill finish.

Warsaw

Our Warsaw site is one of the largest biologics manufacturing sites in Europe, with capabilities for preclinical, clinical and commercial supply to EU and US standards.

Utrecht

Our Utrecht site is one of innovation and leads the discovery, optimization and development of novel biologics and biosimilars as well as being home to our industry leading cell line development platform.

Our sites

Learn more

Gdańsk

Our Gdansk site includes mammalian and microbial R&D and manufacturing facilities for mid-scale production including drug product and fill finish.
Warsaw

Our Warsaw site is one of the largest biologics manufacturing sites in Europe, with capabilities for preclinical, clinical and commercial supply to EU and US standards.
Utrecht

Our Utrecht site is one of innovation and leads the discovery, optimization and development of novel biologics and biosimilars as well as being home to our industry leading cell line development platform.